Tango Therapeutics, Inc. (TNGX) · Aug 11, 2026 · Earnings

Clinical momentum largely confirmed, but quarterly loss exceeded expectations

Clinical momentum largely confirmed, but quarterly loss exceeded expectations

The quarter missed on the only clean consensus metric. The published consensus was roughly a $0.32 loss per share with no revenue expected; Tango reported a $0.37 loss, a five-cent miss, while revenue was indeed $0.

MetricQ2 2026Q2 2025 / expectationRead
Collaboration revenue$0$3.2 million prior year; $0 expectedIn line with the post-Gilead setup (Unaudited Consolidated Statements of Operations)
Research and development expense$37.2 million$32.8 million prior yearHigher as clinical programs advance (Unaudited Consolidated Statements of Operations)
General and administrative expense$22.6 million$11.3 million prior yearSharp increase tied partly to personnel and stock compensation (Unaudited Consolidated Statements of Operations)
Net loss per share$(0.37)$(0.35) prior year; approximately $(0.32) consensusWorse than expected (Unaudited Consolidated Statements of Operations)
Cash, cash equivalents and marketable securities$1.0 billion$343.1 million at December 31, 2025Provides substantial funding for the stated operating plan (Unaudited Consolidated Balance Sheets)

The headline clinical result is confirmation, not a fresh surprise. The 92% objective response rate and 90% six-month progression-free survival rate for vopimetostat plus daraxonrasib had already been reported in June, so this filing mainly repeats those encouraging early-stage data rather than delivering a new readout (Clinical Pipeline Updates — Vopimetostat). The planned October 2026 ESMO presentation and work toward a Phase 3 design are meaningful next steps, but the registrational path remains under discussion with regulators and Revolution Medicines rather than finalized (Clinical Pipeline Updates — Vopimetostat; Upcoming Expected Milestones).

The company is visibly preparing for commercialization, but that also raises spending expectations. Appointing a chief commercialization officer and naming a new board chairman support Tango’s shift from research toward late-stage development and launch planning (Corporate Updates — Executive Leadership; Corporate Updates — Board of Directors). They do not yet change the probability of approval or provide a new commercial forecast, while general and administrative expense nearly doubled year over year (Unaudited Consolidated Statements of Operations).

Net: strategically on track, financially a little worse than expected. The strong cash balance reduces near-term financing pressure, and the pancreatic-cancer program remains the central value driver. But because the positive efficacy data were already known and the quarter produced no new clinical evidence or finalized Phase 3 plan, the filing does not add a comparable upside surprise to offset the five-cent EPS miss.

Original filing on SEC EDGAR

More Tango Therapeutics, Inc. news

Clinical momentum largely confirmed, but quarterly loss exceeded expectations | TNGX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.